OTCMKTS:NWPHF

Newron Pharmaceuticals News Headlines

$2.80
+0.01 (+0.36 %)
(As of 06/8/2021)
Add
Compare
Today's Range
$2.80
$2.80
50-Day Range
$2.80
$2.80
52-Week Range
$1.80
$3.00
Volume2,000 shs
Average Volume3,417 shs
Market Capitalization$49.98 million
P/E RatioN/A
Dividend YieldN/A
Beta0.57

Media Mentions By Week

Newron Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NWPHF
News Sentiment

0.50

0.32

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NWPHF Articles
This Week

3

0

NWPHF Articles
Average Week

Get Newron Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NWPHF and its competitors with MarketBeat's FREE daily newsletter.

Newron Pharmaceuticals (OTCMKTS NWPHF) News Headlines Today

SourceHeadline
Newron Announces Half-Year 2021 ResultsNewron Announces Half-Year 2021 Results
finance.yahoo.com - September 16 at 9:33 AM
Short Interest in Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Decreases By 98.7%Short Interest in Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Decreases By 98.7%
americanbankingnews.com - September 14 at 4:56 PM
Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)Newron Receives Fourth Tranche from Financing Agreement with European Investment Bank (EIB)
finance.yahoo.com - September 6 at 5:01 PM
Newron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Short Interest Up 7,600.0% in AugustNewron Pharmaceuticals S.p.A. (OTCMKTS:NWPHF) Short Interest Up 7,600.0% in August
americanbankingnews.com - August 26 at 2:11 PM
Newron announces Paragraph IV ANDA filings for Xadago® (safinamide) in the USANewron announces Paragraph IV ANDA filings for Xadago® (safinamide) in the USA
uk.finance.yahoo.com - May 20 at 2:06 AM
BRIEF-Supernus Pharmaceuticals Says Co, Newron Received Notice Letters From MSN, Optimus & ZenaraBRIEF-Supernus Pharmaceuticals Says Co, Newron Received Notice Letters From MSN, Optimus & Zenara
msn.com - May 19 at 8:58 PM
Newron Announces Paragraph IV ANDA Filing for Xadago® (safinamide) in the USANewron Announces Paragraph IV ANDA Filing for Xadago® (safinamide) in the USA
finance.yahoo.com - May 4 at 9:50 AM
DGAP-News: Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophreniaDGAP-News: Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia
marketwatch.com - April 2 at 8:05 AM
Newron Pharmaceuticals S.p.A. (NWPHF)Newron Pharmaceuticals S.p.A. (NWPHF)
ca.finance.yahoo.com - March 28 at 6:03 PM
Newron Pharmaceuticals S.p.A.: Newron announces 2020 financial results and provides outlook for 2021Newron Pharmaceuticals S.p.A.: Newron announces 2020 financial results and provides outlook for 2021
finanznachrichten.de - March 16 at 10:10 AM
DGAP-News: Newron announces 2020 financial results and provides outlook for 2021DGAP-News: Newron announces 2020 financial results and provides outlook for 2021
marketwatch.com - March 16 at 10:10 AM
Newron Announces 2020 Financial Results and Provides Outlook For 2021Newron Announces 2020 Financial Results and Provides Outlook For 2021
finance.yahoo.com - March 16 at 10:10 AM
DGAP-News: Newron and Zambon sign agreement for potentially pivotal study with safinamide in Parkinsons disease patientsDGAP-News: Newron and Zambon sign agreement for potentially pivotal study with safinamide in Parkinson's disease patients
marketwatch.com - March 15 at 8:52 AM
Newron and Zambon Sign Agreement for Potentially Pivotal Study with safinamide in Parkinson’s Disease PatientsNewron and Zambon Sign Agreement for Potentially Pivotal Study with safinamide in Parkinson’s Disease Patients
finance.yahoo.com - March 15 at 8:52 AM
Newron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease PatientsNewron Signs Agreement for Starting a Potentially Pivotal Study With Safinamide in Parkinson’s Disease Patients
finance.yahoo.com - March 15 at 8:52 AM
DGAP-News: Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patientsDGAP-News: Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients
marketwatch.com - January 22 at 9:12 AM
Newron Completes Enrollment of Explanatory Safety and Efficacy Study With Evenamide in Schizophrenia PatientsNewron Completes Enrollment of Explanatory Safety and Efficacy Study With Evenamide in Schizophrenia Patients
finance.yahoo.com - January 21 at 8:42 AM
Newron Announces Half-Year 2020 ResultsNewron Announces Half-Year 2020 Results
finance.yahoo.com - September 15 at 8:57 AM
Newron Pharmaceuticals Provides Clinical and Business UpdateNewron Pharmaceuticals Provides Clinical and Business Update
businesswire.com - August 11 at 10:04 PM
Newron Pharmaceuticals issues clinical updateNewron Pharmaceuticals issues clinical update
seekingalpha.com - August 11 at 5:04 PM
Newron Pharmaceuticals to Present at the Jefferies Virtual Healthcare ConferenceNewron Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 29 at 6:28 PM
Newron Reports Top-Line Results From Its STARS Study Evaluating Sarizotan in Patients With Rett SyndromeNewron Reports Top-Line Results From Its STARS Study Evaluating Sarizotan in Patients With Rett Syndrome
finance.yahoo.com - May 4 at 6:25 PM
Newron Receives Third Tranche from Financing Agreement with European Investment Bank (EIB)Newron Receives Third Tranche from Financing Agreement with European Investment Bank (EIB)
finance.yahoo.com - April 15 at 12:56 PM
Newron to report results from key sarizotan study next quarterNewron to report results from key sarizotan study next quarter
seekingalpha.com - March 11 at 2:42 PM
Newron Updates On STARS Study FDA InteractionNewron Updates On STARS Study FDA Interaction
finance.yahoo.com - March 11 at 8:03 AM
BRIEF-Newron Pharmaceuticals FY Net Loss Widens To EUR 20.2 MillionBRIEF-Newron Pharmaceuticals FY Net Loss Widens To EUR 20.2 Million
uk.reuters.com - March 5 at 10:20 AM
Newron Announces 2019 Financial Results and Provides Outlook For 2020Newron Announces 2019 Financial Results and Provides Outlook For 2020
finance.yahoo.com - March 5 at 10:20 AM
Newron Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference in New YorkNewron Pharmaceuticals to Present at the 22nd Annual BIO CEO & Investor Conference in New York
finance.yahoo.com - February 4 at 8:18 AM
Newron Pharmaceuticals focusing on treating Rett syndrome with drug acquired from MerckNewron Pharmaceuticals focusing on treating Rett syndrome with drug acquired from Merck
www.proactiveinvestors.com - January 14 at 10:24 PM
Newron Announces Initiation of New Clinical Trial With Evenamide in Patients With Schizophrenia, Following Approval of Plan By FDANewron Announces Initiation of New Clinical Trial With Evenamide in Patients With Schizophrenia, Following Approval of Plan By FDA
www.businesswire.com - January 9 at 4:24 PM
BRIEF-Newron Receives FDA Rare Pediatric Disease Designation For SarizotanBRIEF-Newron Receives FDA Rare Pediatric Disease Designation For Sarizotan
uk.reuters.com - November 19 at 2:26 PM
Newron nabs RPD tag in U.S. for sarizotan for Rett syndromeNewron nabs RPD tag in U.S. for sarizotan for Rett syndrome
seekingalpha.com - November 19 at 9:25 AM
Those Who Purchased Newron Pharmaceuticals (VTX:NWRN) Shares Three Years Ago Have A 70% Loss To Show For ItThose Who Purchased Newron Pharmaceuticals (VTX:NWRN) Shares Three Years Ago Have A 70% Loss To Show For It
finance.yahoo.com - November 18 at 1:23 PM
Newrons safinamide OKd in Japan for ParkinsonsNewron's safinamide OK'd in Japan for Parkinson's
seekingalpha.com - September 21 at 1:09 AM
Newron Pharma updates on regulatory status of evenamide for schizophreniaNewron Pharma updates on regulatory status of evenamide for schizophrenia
seekingalpha.com - May 28 at 10:34 AM
Get Newron Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NWPHF and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.